Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1. [PDF]
Arias F +28 more
europepmc +1 more source
Effect of the allelic background on the phenotype of primary hyperoxaluria type I. [PDF]
Mandrile G, Cellini B, Ferraro PM.
europepmc +1 more source
Lumasiran at birth changes the trajectory of primary hyperoxaluria type 1: same disease, different outcomes in two affected siblings. [PDF]
Peruzzi L +2 more
europepmc +1 more source
A Minor Haplotype Variant Determines the Pathogenicity of the p.Ile279Thr Substitution in the Primary Hyperoxaluria Type 1 Gene, AGXT. [PDF]
Ruta L +7 more
europepmc +1 more source
Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1. [PDF]
Saffe S +8 more
europepmc +1 more source
Type 1 primary hyperoxaluria in a male infant
Benjamin Waddell, Daniel McKenney
doaj +1 more source
PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1. [PDF]
Lieske JC +10 more
europepmc +1 more source
Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria. [PDF]
Hoppe B +10 more
europepmc +1 more source
Primary Hyperoxaluria With Cardiac Involvement: A Case Series. [PDF]
Ávila DX +7 more
europepmc +1 more source
Primary hyperoxaluria type 1 diagnosis in adult dialysis patients: prediction model assessment in a group of Italian patients. [PDF]
Ferraro PM +16 more
europepmc +1 more source

